Literature DB >> 29278550

Intelligent use of antiepileptic drugs is beneficial to patients.

Jocelyn Y Cheng1, Jacqueline A French.   

Abstract

PURPOSE OF REVIEW: To describe the most important issues a clinician must consider whenever selecting and administering antiepileptic drugs (AEDs). There is no available algorithm that identifies how to individualize selection of AEDs. Proper selection and administration can make an enormous difference in both effectiveness and tolerability. RECENT
FINDINGS: Many principles of AED selection remain unchanged. Selection of AEDs must be based on understanding of epilepsy syndrome and seizure type, comorbidities, risk of adverse events, as well as on patient characteristics such as age and sex. Recently personalized medicine through genetics has become a reality for a subset of patients, to select optimal drugs, and avoid side effects. Selection of AEDs for women can be performed to avoid teratogenic agents, as safer AEDs have been identified. There is evidence supporting use of controlled release AED formulations, whenever available. Whenever selecting an optimal dose, physicians should attend to the principle of 'start low, go slow.' 'Intelligent use' includes not only appropriate drug selection, but also optimal and individualized dose adjustment. Drug optimization involves appropriate titration, dose schedule, individualization of therapeutic range and rescue planning
SUMMARY: Intelligent drug use, individualized to patient characteristics, can guide management for optimal seizure control.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29278550     DOI: 10.1097/WCO.0000000000000532

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  2 in total

Review 1.  Epilepsy in the Elderly: Treatment and Consideration of Comorbid Diseases.

Authors:  Sang Kun Lee
Journal:  J Epilepsy Res       Date:  2019-06-30

2.  Experience of perampanel monotherapy beyond initial titration to achieve seizure freedom in patients with focal-onset seizures with newly diagnosed or currently untreated recurrent epilepsy: A post hoc analysis of the open-label Study 342 (FREEDOM).

Authors:  Ryan Edbert Husni; Leock Y Ngo; Hirofumi Senokuchi; Anna Patten; Hidetaka Hiramatsu; Kazuaki Watanabe; Takamichi Yamamoto
Journal:  Epilepsia Open       Date:  2021-11-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.